Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …

SARS-CoV-2 receptor binding domain (RBD) mediates viral entry into human cells through
its interaction with angiotensin converting enzyme 2 (ACE2). Most neutralizing antibodies …

Abstract HER-1 and HER-2 are tumor-associated antigens overexpressed in several
epithelial tumors, and successfully targeted by therapeutic approaches against cancer …

Abstract Interleukin-2 (IL-2) engineered versions, with biased immunological functions, have
emerged from yeast display and rational design. Here we reshaped the human IL-2 interface …

Background Antitumor therapies targeting HER1/EGFR and HER2, such as monoclonal
antibodies (MAbs) and tyrosine-kinase inhibitors (TKIs), have demonstrated a significant …

Selection from a phage display library derived from human Interleukin-2 (IL-2) yielded
mutated variants with greatly enhanced display levels of the functional cytokine on …

Nimotuzumab is a humanized monoclonal antibody against the Epidermal Growth Factor
Receptor with a long history of therapeutic use, recognizing an epitope different from the …

The current chapter focuses on the use of filamentous phages to display and modify
biologically active cytokines, with special emphasis on directed evolution of novel variants …

High-dose IL2, first approved in 1992, has been used in the treatment of advanced renal cell
carcinoma and melanoma. In these indications, IL2 induces long lasting objective responses …

Protein tyrosine O-sulfation (PTS) is a common post-translational modification that has been
implicated in a variety of biological processes and human illnesses. Despite continued …